Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ — Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data from two pipeline programs that modulate the hepcidin pathway will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, which will be held virtually December 5-8, 2020.

Details of the presentations are as follows:

Abstract Number: 1690
Title: DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin
Date: Sunday, December 6, 2020, 7:00 AM-3:30 PM EST
Session: 102. Regulation of Iron Metabolism: Poster II
Presenter: Vu Hong, PhD, Director and Project Leader

Abstract Number: 2599
Title: DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Decreases Hepcidin and Increases Transferrin Saturation in a Non-Human Primate Model of Cytokine (IL-6) Induced Hypoferremia
Date: Monday, December 7, 2020, 7:00 AM-3:30 PM EST
Session: 102. Regulation of Iron Metabolism: Poster III
Presenter: Maria Beconi, PhD, SVP of Translational Research and Development

Full abstracts are currently available through the ASH conference website: www.hematology.org/Annual-Meeting/Abstracts/.

About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Currently focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

SOURCE Disc Medicine

Related Links

http://www.discmedicine.com

Source Article

Read more

QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND – Press Release

CAMBRIDGE, Mass.–(Business Wire)–QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced that the company will present two posters featuring data from two of the company’s preclinical precision medicine ALS programs at the Motor Neuron Disease Association (MNDA) 31st International Symposium on ALS/MND, being held virtually on December 9-11, 2020.

QurAlis co-founders and Harvard professors Kevin Eggan, Ph.D. and Clifford Woolf, M.D., Ph.D., members of the QurAlis Scientific and Clinical Advisory Boards, Brian Wainger, M.D., Ph.D. (Massachusetts General Hospital) and Merit Cudkowicz, M.D., M.Sc. (Massachusetts General Hospital), and other authors recently published in JAMA Neurology the results of a clinical study investigating the therapeutic potential of Kv7 agonism in ALS. The clinical data support QurAlis’ belief that a safe Kv7 opener could be an effective disease-modifying therapy for ALS patients with motor system hyperexcitability, an approach that QurAlis is pursing with its preclinical program investigating the regulation of the Kv7.2/7.3 ion channel.

The poster presentations will share, for the first time publicly, results from preclinical studies of QurAlis’ program investigating a novel Kv7.2/7.3 ion channel agonist as a potential treatment for motor neuron hyperexcitability and excitotoxicity, as well as its program targeting the TBK1 autophagy pathway.

“While KV7 agonists have shown great potential as a treatment for the 20-50% of ALS patients who present with hyperexcitability in their motor system, they can often cause undesired side effects such as dizziness and fatigue,” said Daniel Elbaum, Ph.D., Chief Scientific Officer of QurAlis. “The preclinical data we will be presenting show that the improved channel specificity of our novel Kv7.2/7.3 agonist could translate into an improved clinical safety profile with significant reduction in off-target adverse events. We look forward to sharing the full results of this preclinical study as well as discussing our autophagy program at the MNDA 31st International Symposium on ALS/MND.”

Details of the presentations are as follows:

Title: TBK1 Autophagy Pathway Disease Mechanisms in ALS

Authors: Erika Norabuena; Clinton Bourbonais; Kasper Roet, Ph.D.; Kevin Eggan, Ph.D.; Daniel Elbaum, Ph.D.; Sandy Hinckley, Ph.D.

Presenting Author: Erika Norabuena

Date/Time: December 9, 2020, 12:10pm-12:50pm ET

Poster/Abstract Number: TST-07

Link to abstract

Title: QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients

Authors: Daniel Elbaum, Ph.D.; Sandy Hinckley, Ph.D.; Kasper Roet, Ph.D.

Presenting Author: Daniel Elbaum, Ph.D.

Date/Time: December 11, 2020, 7:05am-7:50am ET

Poster/Abstract Number: TST-20

Link to abstract

About ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease impacting nerve cells in the brain and spinal cord. ALS breaks down nerve cells, reducing muscle function and causing loss of muscle control. ALS can be traced to mutations in over 25 different genes and is often caused by a combination of multiple sub-forms of the condition. Its average life expectancy is three years, and there is currently no cure for the disease.

About QurAlis Corporation

QurAlis is bringing hope to the

Read more

Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ — Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating diseases, announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic diseases. (PRNewsfoto/Disc Medicine)

A pre-recorded presentation by John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will be available beginning on Monday, November 23 at 10:00 am Eastern Standard Time. A link to the presentation will be provided in the “News & Events” section of Disc Medicine’s website at www.discmedicine.com.

About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Currently focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/disc-medicine-to-present-at-the-piper-sandler-32nd-annual-healthcare-conference-301178870.html

SOURCE Disc Medicine

Source Article

Read more

Change Healthcare to Present at the Credit Suisse 29th Annual Healthcare Conference

Change Healthcare Inc. (Nasdaq: CHNG), a leading independent healthcare technology company, today announced its participation in a virtual fireside chat via webcast at the Credit Suisse 29th Annual Healthcare Conference on Wednesday, Nov. 11, 2020 at 11:00 a.m. Eastern Time.

The live webcast and more information about this event may be accessed by visiting the Events and Presentations tab at http://ir.changehealthcare.com. The webcast replay will be available approximately 48 hours after the live webcast ends and will be accessible for 90 days following the conference.

About Change Healthcare

Change Healthcare (Nasdaq: CHNG) is a leading independent healthcare technology company, focused on insights, innovation, and accelerating the transformation of the U.S. healthcare system through the power of the Change Healthcare Platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.

Learn more at changehealthcare.com.

CHNG-IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005185/en/

Contacts

Evan Smith, CFA
Investor Relations
404-338-2225
[email protected]

Source Article

Read more

Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel

SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. Dr. Hasan Jafri, Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.”

Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus
Date: Wednesday, October 28, 2020
Time: 10:30AM-11:50AM ET

Dr. Jafri will present a summary of the Company’s recently published preclinical data of its COVID-19 inhaled mAb (AR-711). He will address the preclinical performance of AR-711, the advantages of direct lung delivery using nebulized aerosols, and the COVID-19 clinical program.

About AR-711

AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients. AR-711 exhibits high affinity for SARS-CoV-2 spike protein, approximately 10-fold or higher than mAb candidates currently in late stage clinical testing. AR-711 was previously shown to be effective in prophylactic as well as therapeutic treatment modes in a SARS-CoV-2 viral challenge study. AR-711 is currently being developed as an inhaled, self-administered treatment for non-hospitalized patients suffering from mild to moderate COVID-19. AR-711 is also one the two mAbs in the company’s AR-701 mAb cocktail, which is a separate program being developed as an intravenous treatment of moderate to severe, hospitalized COVID-19 patients.

About Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ʎPEXTM and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor’s immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.

The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company’s pipeline is highlighted below:

Aridis’ Pipeline

AR-301 (VAP). AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive 

Read more

Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, announced today the presentation of new clinical data on an improved tablet formulation of its liver-distributed farnesoid X receptor (FXR) agonist TERN-101 at the Paris NASH Digital Experience, taking place virtually October 22-23, 2020. The presentation, entitled “Comparative pharmacokinetics of two oral formulations of nonsteroidal farnesoid X receptor agonist TERN-101 in healthy volunteers,” demonstrated that an amorphous tablet formulation of TERN-101, which is currently being evaluated in the Phase 2a LIFT study in NASH patients, achieved faster absorption and higher plasma levels compared to a previous crystalline capsule formulation of TERN-101. The study results also demonstrate that the new formulation reduces pharmacokinetic variability and that TERN-101 can be administered without regard to food.

“In Terns’ Phase 1 studies, TERN-101 has demonstrated potent FXR activation in the liver and is well tolerated, with no observation of pruritus and no difference from placebo in serum lipid effects. We’ve now developed an improved formulation that optimizes absorption and minimizes PK variability,” said Erin Quirk, M.D., President and Chief Medical Officer of Terns. “This new TERN-101 formulation is now being studied in our 12-week Phase 2a LIFT study in NASH patients, and we look forward to seeing the results in mid-2021.”

Full details from the presentation can be found at www.ternspharma.com/scientific-publications.

About TERN-101 and Farnesoid X Receptor (FXR) Agonism

TERN-101 is a potent, non-steroidal FXR agonist, with enhanced liver distribution being developed for the treatment of NASH. FXR is a nuclear receptor that is highly expressed in the liver and small intestine. FXR agonism has demonstrated improvement over placebo in regression of histological liver fibrosis without progression of NASH in a late-stage study, demonstrating the potential for FXR agonists to be a new treatment modality for NASH. TERN-101 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of NASH.

About NASH

Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis, and eventually liver cancer or liver failure. Global rates of NAFLD and NASH are increasing rapidly, in tandem with rising rates of obesity. There is currently no approved medication for the treatment of NASH.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases. The company’s liver-selective FXR-agonist, TERN-101, is currently conducting a multi-center, randomized, double-blind, placebo-controlled Phase 2a clinical trial designed to evaluate efficacy, safety, and pharmacokinetics in 96 presumed NASH patients who receive placebo or TERN-101 at various dose levels for 12 weeks. Terns recently announced positive Phase 1 clinical data for its highly selective SSAO inhibitor, TERN-201, demonstrating potent and sustained target engagement. In addition,

Read more

Galacto-oligosaccharide Market | Europe to Present Significant Growth Opportunities Through 2024

The global galacto-oligosaccharide market is expected to grow by USD 486.79 million as per Technavio’s market research report. The analysis of the impact of COVID-19 on the market reveals a market slowdown in the first half of 2020,. However, the effect will gradually lessen in the coming quarters. In addition, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of 10%. . Request Free Sample Report on COVID-19 Impacts

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005537/en/

Technavio has announced its latest market research report titled Global Galacto-oligosaccharide Market 2020-2024 (Graphic: Business Wire)

Read the 120-page report with TOC on “Galacto-oligosaccharide Market Analysis Report by Product (Syrup and Powder), Geography (Europe, North America, Asia, and ROW), and the Segment Forecasts, 2020-2024”. https://www.technavio.com/report/galacto-oligosaccharide-market-size-industry-analysis

The market is driven by the health benefits of galacto-oligosaccharides. In addition, the use of nutraceuticals and prebiotics in treating chronic diseases is anticipated to boost the growth of the galacto-oligosaccharide market.

Galacto-oligosaccharides are prebiotics and non-digestible food ingredients. They stimulate the activity of gut bacteria, which improves immunity, enhance the absorption of essential nutrients, and produce powerful antioxidant H2 gas. Galacto-oligosaccharides also inhibit the binding or survival of opportunistic microorganisms, such as Escherichia coli, Salmonella Typhimurium, and Clostridia. They can also influence the immune system by producing antimicrobial substances and inhibit the growth of pathogenic bacteria. Many such health benefits are fueling the growth of the global galacto-oligosaccharide market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Galacto-oligosaccharide Companies:

Clasado Biosciences

Clasado Biosciences operates its business through a unified segment. The company offers Bimuno, which is a daily fiber supplement containing galacto-oligosaccharides, which feeds and stimulates the growth of good bacteria in the gut.

Fonterra Co operative Group Ltd.

Fonterra Co operative Group Ltd. operates its business through segments such as Ingredients, Consumer and foodservice, and China Farms. The company offers NZMP SureStart GOS, which is a prebiotic supplement added to infant formula products to make them closer to the composition of breast milk for mothers who cannot or choose not to breastfeed.

Ingredion Inc.

Ingredion Inc. operates its business through segments such as North America, South America, Asia Pacific, and EMEA. The company offers BIOLIGO GL 5700 IMF. It is a soluble dietary fiber made from lactose in the form of a syrup that contains 57% galacto-oligosaccharide.

Lactose (India) Ltd.

Lactose (India) Ltd. operates its business through a unified segment. The company offers galacto-oligosaccharide produced through the enzymatic conversion of lactose and is available in the powder form.

New Francisco (Yunfu City) Biotechnology Corp. Ltd.

New Francisco (Yunfu City) Biotechnology Corp. Ltd. operates its business through a unified segment. The company offers products such as GOS-270-P, GOS-700-P, and GOS-800-P.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Galacto-oligosaccharide Market Product Outlook (Revenue,

Read more

USC Environmental Overall health Centers Present News, Events And Investigation Projects Of The Environmental Overall health Centers

The Health-related College is renowned for preparing its students to be world class physicians. NHS Bursaries are presently available for eligible Medicine students from Year five of the Common Course (A100), or from Year two of the Graduate Course (A101). The TFG includes students finishing their own original analysis projects that consist of and expand upon on topics studied on the course and require students to use the skills and abilities they have acquired throughout their degree.

A report written up in the Medical Journal of Australia particulars the death of a 75 year old male who had a prostate cancer scare. The AAMC’s 2016 Healthcare School Enrollment Survey discovered that 80% of schools were concerned about the number of available clinical coaching web sites.

Or, la compostion de la nouvelle Commission strategy de vaccination, rattachée à la HAS, qui a pour présidente le Pr Elizabeth Bouvet, n’est pas de nature à renforcer la confiance. Our vision to bring trauma relief to communities that want it most is boosted by our strategic partnerships with major medical institutions and relief agencies.

Diving medicine (or hyperbaric medicine ) is the prevention and treatment of diving-related troubles. The new $35 million center, which will allow cancer sufferers to undergo cutting edge proton therapy in single-space treatment options, is expected to be completed by 2020.

The Division of Cardiovascular Medicine is a dynamic and revolutionary center committed to excellence in investigation, health-related education, and clinical care. To allow a new era of medicine by way of research, technologies, and policies that empower patients, researchers, and providers to function with each other toward improvement of individualized care.…

Read more